At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 6:17:03 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 7 | 12 | 12 |
| Avg. Estimate | -0.1 | -0.19 | -0.7 | 0.24 |
| Low Estimate | -0.4 | -0.27 | -1.06 | -0.94 |
| High Estimate | 0.22 | -0.13 | -0.35 | 1.32 |
| Year Ago EPS | -0.3 | -0.16 | -1.46 | -0.7 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 7 | 14 | 14 |
| Avg. Estimate | 194.05M | 197.76M | 675.68M | 935.54M |
| Low Estimate | 187.9M | 187.84M | 669.6M | 857M |
| High Estimate | 199.4M | 207.57M | 681M | 1.02B |
| Year Ago Sales | 132.1M | 144.87M | 464.37M | 675.68M |
| Sales Growth (year/est) | 46.90% | 36.51% | 45.51% | 38.46% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.46 | -0.32 | -0.18 | -0.2 |
| EPS Actual | -0.3 | -0.16 | -0.16 | -0.25 |
| Difference | 0.16 | 0.16 | 0.02 | -0.05 |
| Surprise % | 35.10% | 50.52% | 13.20% | -27.52% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.1 | -0.19 | -0.7 | 0.24 |
| 7 Days Ago | -0.11 | -0.18 | -0.68 | 0.21 |
| 30 Days Ago | -0.08 | -0.18 | -0.68 | 0.23 |
| 60 Days Ago | -0.15 | -0.09 | -0.67 | 0.45 |
| 90 Days Ago | -0.14 | -0.09 | -0.67 | 0.4 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | -- |
| Up Last 30 Days | 9 | 1 | 3 | 3 |
| Down Last 7 Days | -- | 5 | -- | 1 |
| Down Last 30 Days | 4 | 5 | 10 | 9 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ITCI | 65.25% | -18.75% | 51.90% | 133.94% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 11/4/2024 |
| Reiterates | Needham: Buy to Buy | 10/31/2024 |
| Reiterates | Needham: Buy to Buy | 10/30/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 10/11/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 10/4/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/20/2024 |
Related Tickers
AVDL Avadel Pharmaceuticals plc
10.39
-2.07%
NBIX Neurocrine Biosciences, Inc.
126.70
-0.07%
DERM Journey Medical Corporation
5.09
+0.59%
AQST Aquestive Therapeutics, Inc.
3.6100
-2.17%
ALKS Alkermes plc
30.51
+0.03%
PCRX Pacira BioSciences, Inc.
19.86
+0.30%
LNTH Lantheus Holdings, Inc.
93.02
+1.21%
SIGA SIGA Technologies, Inc.
6.18
+0.49%
IRWD Ironwood Pharmaceuticals, Inc.
3.5300
-0.84%
PBH Prestige Consumer Healthcare Inc.
82.30
-1.53%